Sign Up to like & get
recommendations!
1
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e17543
Abstract: e17543Background: 177Lu-labelled prostate-specific membrane antigen (LuPSMA) radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) is currently under investigation in phas...
read more here.
Keywords:
177lu psma;
radionuclide;
efficacy safety;
safety 177lu ... See more keywords